Table 1.

Pharmacokinetic data of selegiline and rasagiline.

Parameters	Selegiline [61]	Rasagiline [62]
Cmax (µg/L)	2.20 ± 1.17	17.55 ± 3.51, PD, 14.9 ± 10.5
Tmax (h)	0.90 ± 0.38	0.4 ± 0.2, PD, 0.5 ± 0.7
T1/2 (h)	1.20 ± 0.56	2.06 ± 1.14, PD, nr
AUC (µg.h/L)	3.75 ± 0.28	20.02 ± 4.81, PD, 23.5 ± 10.5
CL/F (L/min)	59.4 ± 43.7	33.6 ± 7.8, PD, nr
Bioavailability (%)	<10	36

Selegiline (10 mg/day) was once only orally administered to healthy human subjects [61], and rasagiline (2 mg/day) to control and PD patients as an adjunct to L-DOPA UC, area under the plasma concentration-time curve; CL/F, apparent total body clearance; C_max, maximal plasma content; T_max, time to reach the maximal level; T_1/2, half-life time. nr, not reported; PD, parkinsonian patients.